Effectiveness of Cyclosporine in a 10-year-old Girl with C3 Glomerulopathy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
C3 glomerulopathy (C3G) is a recently defined pathological entity characterized by C3 accumulation with absent or scant immunoglobulin deposition, leading to variable glomerular inflammation. The clinical presentation of patients with C3G is highly variable, as they may present with symptoms ranging from microscopic or mild proteinuria to full-blown nephrotic syndrome, with or without renal impairment. However, there is no consensus recommendation for specific treatment in children with C3G. Recently, new therapies have been suggested to target complement pathways, owing to an improvement in the understanding of the pathogenesis of C3G. C3G complement blockade with eculizumab, a monoclonal antibody targeted against complement C5, inhibits activation of the alternative complement pathway. We could not use eculizumab owing to its high price; thus, we administered oral prednisolone and mycophenolate mofetil (MMF). MMF was replaced with cyclosporine because proteinuria persisted, with a consistently low serum C3 level; we tapered off the prednisolone because of a Cushingoid appearance and amenorrhea. Thereafter, proteinuria improved, and the serum C3 level returned to normal. Thus, we report the effectiveness of cyclosporine in a patient with C3G and an inadequate response to prednisolone and MMF, who was detected via school urinary screening.
Abstract
C3 glomerulopathy (C3G) is a recently defined pathological entity characterized by C3 accumulation with absent or scant immunoglobulin deposition, leading to variable glomerular inflammation. The clinical presentation of patients with C3G is highly variable, as they may present with symptoms ranging from microscopic or mild proteinuria to full-blown nephrotic syndrome, with or without renal impairment. However, there is no consensus recommendation for specific treatment in children with C3G. Recently, new therapies have been suggested to target complement pathways, owing to an improvement in the understanding of the pathogenesis of C3G. C3G complement blockade with eculizumab, a monoclonal antibody targeted against complement C5, inhibits activation of the alternative complement pathway. We could not use eculizumab owing to its high price; thus, we administered oral prednisolone and mycophenolate mofetil (MMF). MMF was replaced with cyclosporine because proteinuria persisted, with a consistently low serum C3 level; we tapered off the prednisolone because of a Cushingoid appearance and amenorrhea. Thereafter, proteinuria improved, and the serum C3 level returned to normal. Thus, we report the effectiveness of cyclosporine in a patient with C3G and an inadequate response to prednisolone and MMF, who was detected via school urinary screening.
참고문헌 (22)
- Sethi S, "C3glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up", Kidney Int, 82, pp.465~473 (2012)
- Pickering MC, "C3 glomerulopathy: consensus report", Kidney Int, 84, pp.1079~1089 (2013)
- Bomback AS, "Pathogenesis of the C3 glomerulopathies and reclassification of MPGN", Nat Rev Nephrol, 8, pp.634~642 (2012)
- Smith RJ, "New approaches to the treatment of dense deposit disease", J Am Soc Nephrol, 18, pp.2447~2456 (2007)
- Nester CM, "Diagnosis and treatment of C3 glomerulopathy", Clin Nephrol, 80, pp.395~403 (2013)
- Medjeral-Thomas NR, "C3 glomerulopathy: clinicopathologic features and predictors of outcome", Clin J Am Soc Nephrol, 9, pp.46~53 (2014)
- Fakhouri F, "C3 glomerulopathy: a new classification", Nat Rev Nephrol, 6, pp.494~499 (2010)
- Master Sankar Raj V, "Overview of C3 Glomerulopathy", Front Pediatr, 4 (2016)
- Barbour TD, "Recent insights into C3 glomerulopathy", Nephrol Dial Transplant, 28, pp.1685~1693 (2013)
- Cameron JS, "Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis", Am J Med, 74, pp.175~192 (1983)
- Little MA, "Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk", Kidney Int, 69, pp.504~511 (2006)
- Servais A, "Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies", Kidney Int, 82, pp.454~464 (2012)
- Daina E, "Eculizumab in a Patient with Dense-Deposit Disease", N Engl J Med, 366, pp.1161~1163 (2012)
- Rabasco C, "Effectiveness of mycophenolate mofetil in C3 glomerulonephritis", Kidney Int, 88, pp.1153~1160 (2015)
- Lioufas N, "Durable remission of C3 glomerulonephritis with mycophenolate mofetil", Nephrology (Carlton), 22(Suppl 1), pp.36~39 (2017)
- Goodship THJ, "Atypical hemolytic uremic syndrome and C3glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference", Kidney Int, 91, pp.539~551 (2017)
- Bagheri N, "Cyclosporine in the treatment of membranoproliferative glomerulonephritis", Arch Iran Med, 11, pp.26~29 (2008)
- Ruseva MM, "Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy", J Am Soc Nephrol, 27, pp.405~416 (2016)
- Lebreton C, "C3 glomerulopathy and eculizumab: a report on four paediatric cases", Pediatr Nephrol, 32, pp.1023~1028 (2017)
- Kiyomasu T, "Cyclosporin A Treatment for Membranoproliferative Glomerulonephritis Type II", Nephron, 91, pp.509~511 (2002)
- Lee S-J, "A Case of Membranoproliferative Glomerulonephritis Type II(Dense-Deposit Disease)", Child Kidney Dis, 7, pp.204~210 (2003)
- Singh A, "One-center experience with cyclosporine in refractory nephrotic syndrome in children", Pediatr Nephrol, 13, pp.26~32 (1999)